[go: up one dir, main page]

Targonskaya et al., 2023 - Google Patents

Gonadotropin and ovarian hormone monitoring: Lateral flow assays for clinical decision making

Targonskaya et al., 2023

View HTML
Document ID
14615378257943598532
Author
Targonskaya A
Maslowski K
Publication year
Publication venue
Women

External Links

Snippet

FSH, estrogen and progesterone testing are widely utilized in clinical practice. Lateral flow assays (LFAs) are cost-effective tools used for diagnosing infectious diseases, pregnancy, and substance testing. The focus of this narrative review is the potential for the wider …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions

Similar Documents

Publication Publication Date Title
Rudnicka et al. Anti-Müllerian hormone in pathogenesis, diagnostic and treatment of PCOS
Peña et al. Criteria for diagnosis of polycystic ovary syndrome during adolescence: literature review
Trost et al. Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials
O’Neill et al. Gestational diabetes alters the metabolomic profile in 2nd trimester amniotic fluid in a sex-specific manner
Sivanandy et al. The role of serum anti-mullerian hormone measurement in the diagnosis of polycystic ovary syndrome
Keevil Steroid mass spectrometry for the diagnosis of PCOS
Ahmed et al. Serum anti-Müllerian hormone in the diagnosis of polycystic ovary syndrome in association with clinical symptoms
Grassi et al. Hyperandrogenism by liquid chromatography tandem mass spectrometry in PCOS: focus on testosterone and androstenedione
Lee et al. Effect of urinary bisphenol A on androgenic hormones and insulin resistance in preadolescent girls: a pilot study from the Ewha Birth & Growth Cohort
Bouchard et al. Establishing a gold standard for quantitative menstrual cycle monitoring
Hamidovic et al. Reduced Dehydroepiandrosterone-sulfate levels in the mid-luteal subphase of the menstrual cycle: implications to women’s health research
Konishi et al. Coital frequency and the probability of pregnancy in couples trying to conceive their first child: a prospective cohort study in Japan
Menzhinskaya et al. Potential significance of serum autoantibodies to endometrial antigens, α-Enolase and hormones in non-invasive diagnosis and pathogenesis of endometriosis
Aleksandra et al. Erectile dysfunction in relation to metabolic disorders and the concentration of sex hormones in aging men
Paczkowska et al. Specific alteration of branched-chain amino acid profile in polycystic ovary syndrome
Khashchenko et al. Pelvic pain, mental health and quality of life in adolescents with endometriosis after surgery and dienogest treatment
Kolatorova et al. COVID-19, vaccination, and female fertility in the Czech Republic
Fitzpatrick et al. Advances in precision health and emerging diagnostics for women
Ursache et al. Vitamin D—The Iceberg in Endometriosis—Review and Meta-Analysis
Birchenall et al. Metabolite changes in maternal and fetal plasma following spontaneous labour at term in humans using untargeted metabolomics analysis: a pilot study
Almomin et al. Trimester-specific reference intervals of thyroid function testing in pregnant women from Basrah, Iraq using electrochemiluminescent immunoassay
Chatziandreou et al. Antimüllerian hormone as a tool to predict the age at menopause
Targonskaya et al. Gonadotropin and ovarian hormone monitoring: Lateral flow assays for clinical decision making
Kolcsar et al. Anti-Müllerian hormone level determinants among non-polycystic-ovary-syndrome women undergoing in vitro fertilization: a retrospective cross-sectional study
Kowalcze et al. The impact of maternal hypothyroidism during pregnancy on minipuberty in boys